Qian-Jin Zhang to Cell Line, Tumor
This is a "connection" page, showing publications Qian-Jin Zhang has written about Cell Line, Tumor.
Connection Strength
0.305
-
Li XL, Sluijter M, Doorduijn EM, Kale SP, McFerrin H, Liu YY, Li Y, Mottamal M, Yao X, Du F, Gu B, Hoang K, Nguyen YH, Taylor N, Stephens CR, van Hall T, Zhang QJ. Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase. PLoS One. 2014; 9(11):e108192.
Score: 0.077
-
Sun Y, Yan K, Wang Y, Xu C, Wang D, Zhou W, Guo S, Han Y, Tang L, Shao Y, Shan S, Zhang QC, Tang Y, Zhang L, Xi Q. Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5. Nat Cancer. 2022 09; 3(9):1105-1122.
Score: 0.033
-
Chowdhury N, Chaudhry S, Hall N, Olverson G, Zhang QJ, Mandal T, Dash S, Kundu A. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment. AAPS PharmSciTech. 2020 Jul 21; 21(6):202.
Score: 0.029
-
Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). J Med Chem. 2016 09 08; 59(17):8134-40.
Score: 0.022
-
Zhong Q, Zhang C, Zhang Q, Miele L, Zheng S, Wang G. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status. BMC Cancer. 2015 Sep 09; 15:625.
Score: 0.020
-
Zhang C, Zhong Q, Zhang Q, Zheng S, Miele L, Wang G. Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):283-91.
Score: 0.020
-
Zheng S, Zhong Q, Xi Y, Mottamal M, Zhang Q, Schroeder RL, Sridhar J, He L, McFerrin H, Wang G. Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. J Med Chem. 2014 Aug 14; 57(15):6653-67.
Score: 0.019
-
Zheng S, Zhong Q, Mottamal M, Zhang Q, Zhang C, Lemelle E, McFerrin H, Wang G. Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents. J Med Chem. 2014 Apr 24; 57(8):3369-81.
Score: 0.019
-
Kasowski M, Kyriazopoulou-Panagiotopoulou S, Grubert F, Zaugg JB, Kundaje A, Liu Y, Boyle AP, Zhang QC, Zakharia F, Spacek DV, Li J, Xie D, Olarerin-George A, Steinmetz LM, Hogenesch JB, Kellis M, Batzoglou S, Snyder M. Extensive variation in chromatin states across humans. Science. 2013 Nov 08; 342(6159):750-2.
Score: 0.018
-
Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E, Bratton MR, Zhang Q, Wang G. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013 Sep; 12(9):2440-55.
Score: 0.017
-
Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012 Mar 14; 14(2):R45.
Score: 0.016
-
Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26; 53(16):6153-63.
Score: 0.014